![]() |
Data Suggests Improved Disease Control With FASLODEXTM 500mg Compared With Anastrozol
New data presented at the CTRC-AACR 33rd Annual San Antonio Breast Cancer Symposium, USA, suggest fulvestrant 500mg offers improved disease control compared with the aromatase inhibitor, anastrozole, when used as a first-line treatment* for hormone receptor positive breast cancer...
More... |
| All times are GMT -7. The time now is 08:20 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021